ONCY · Categories · Offerings
ONCY - Public offerings
Oncolytics Biotech Inc. (ONCY) public offerings - real-time wire coverage filtered to Offerings only.
Recent Offerings for ONCY
- Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni CapitalSAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key clinical milestones and minimize dilution to create and sustain shareholder value. The SPA allows Oncolytics to be judicious and plan for the timing and amount of any equity sales, which will be critical as pelareorep's development continues. Under the terms of the agreeme
- Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing Cash position of $15.9 million provides runway through critical milestones into third quarter 2025 Management hosting conference call and webcast this morning at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, March 7, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results fo
- Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology TreatmentsUSA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 18, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that highlighted how their scientists continued to set the standard for research and innovation over the course of the year. However, along with the report's optimism, the American Cancer Society also recently released a study finding that early-onset colorectal cancer cases are surging globally, signaling an alarming trend. A new article published in Nature showed that the COVID-19 pandemic severely disrupted cancer care, causing delays in di
- Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational HighlightsBRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort Cash position of $19.6 million as of September 30, 2024 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Nov. 12, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced third quarter financial resul
- Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsPelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX Impressive objective response rate in GOBLET study anal carcinoma cohort supports enrollment expansion Expecting to report overall survival data from BRACELET-1 breast cancer study in 2024 Cash position of $34.9 million provides runway through critical milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, March 7, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announce
- Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsPelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX Impressive objective response rate in GOBLET study anal carcinoma cohort supports enrollment expansion Expecting to report overall survival data from BRACELET-1 breast cancer study in 2024 Cash position of $34.9 million provides runway through critical milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, March 7, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recen
- Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public OfferingCALGARY, AB, Sept. 7, 2023 /CNW/ -- Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (NASDAQ:ONCY) (TSX:ONC) today announced that in connection with the previously announced underwritten public offering of US$15,000,750 (the "Offering") and the underwriting agreement dated August 1, 2023 (the "Underwriting Agreement"), Leede Jones Gable Inc. (the "Underwriter") has exercised their option (the "Over-Allotment Option"), in full, to purchase 1,000,050 units (the "Optioned Units") at US$2.25 for aggregate gross proceeds of US$2,250,112. The Company intends to use the proceeds from the Offering to continue the advancement of its pelareorep clinical programs in metastatic breast and pancre
- Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational HighlightsPhase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression Pelareorep selected for inclusion in the Precision PromiseSM phase 3 platform trial in pancreatic cancer, designed to accelerate registration path and reduce by ~50% phase 3 costs compared to traditional trial $24.4 million in cash, cash equivalents and marketable securities as of June 30, 2023 provides projected runway into H2 2024 Strengthened financial position with a successful US$15 million public offering on August 8, 2023 Management hosting conference call and webcast today at 8:30 a.m. ET
- Oncolytics Biotech® Successfully Raises US$15 Million to Advance Breast and Pancreatic Cancer Clinical ProgramsCALGARY, Alberta, Aug. 8, 2023 /CNW/ -- Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (NASDAQ:ONCY) (TSX:ONC) today announced the closing (the "Closing") of the previously announced underwritten public offering of US$15,000,750 (the "Offering"). An institutional investor was a significant participant in the Offering. The Company intends to use the proceeds from the Offering to continue the advancement of its pelareorep clinical programs in metastatic breast and pancreatic cancers, as well as general corporate and working capital purposes. Leede Jones Gable Inc. acted as underwriter and bookrunner (the "Underwriter") in accordance with the terms of an underwriting agreement between
- Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of UnitsNot for distribution to U.S. Newswire Services or Dissemination in the United States CALGARY, AB, July 31, 2023 /CNW/ -- Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (NASDAQ:ONCY) (TSX:ONC) today announced that it has entered into an agreement with Leede Jones Gable Inc. as underwriter and bookrunner (the "Underwriter"), pursuant to which the Underwriter has agreed to purchase, on a bought-deal basis, 6,667,000 units (the "Equity Units") for gross proceeds to the Company of US$15,000,750 (the "Offering") at a price of US$2.25 per Equity Unit. Each Equity Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (each whole purc
- Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational HighlightsRandomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022 Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker – a key finding for de-risking a phase 3 registrational breast cancer study Interim safety updates from clinical trials in triple-negative breast and gastrointestinal cancers further demonstrate the favorable safety profile of pelareorep-checkpoint inhibitor combinations Strong financial position with approximately $41.3 million and cash runway through key milestones and into 2023 Management hosting conference call and webcast today at 5:00 p.m. ET SAN DIEGO and CALGARY,